Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, FDA approves three new therapies this week: Priovant Therapeutics' Lisraya for dermatomyositis, Gilead Sciences' Bixlenvo for HIV, and an expanded cardiovascular indication for Eli Lilly's Mounjaro; a dealmaking roundup covers DualityBio's up-to-$1-billion ADC partnership with Genentech and Teva's $57.5 million stalking-horse bid for BioXcel's Igalmi; and Israel Ortiz argues that preventive and predictive maintenance is becoming essential to avoiding costly batch failures in biopharma manufacturing.

Three FDA drug approvals land this week, spanning autoimmune disease, HIV, and cardiometabolic risk. FDA approves Priovant Therapeutics' Lisraya (brepocitinib), a once-daily 30 mg pill and the first targeted therapy for adults with dermatomyositis, after the Phase III Valor trial showed 55% of patients reaching moderate or better improvement with minimal or no steroid use by week 52, more than four times the improvement seen with placebo. Separately, FDA approved Gilead Sciences' Bixlenvo (bictegravir/lenacapavir), the first once-daily single-tablet regimen for virologically suppressed HIV patients coming off complex regimens, based on Phase III Artistry-1 and Artistry-2 data showing sustained viral suppression at week 48. Finally, FDA expanded the label for Eli Lilly's Mounjaro (tirzepatide) to reduce major adverse cardiovascular events in high-risk type 2 diabetes patients, with the Surpass-CVOT trial in more than 13,000 participants showing an 8% lower cardiovascular event rate versus Trulicity.

Two dealmaking headlines round out the week, as DualityBio, a biotech focused on antibody-drug conjugates, licenses its Dupac ADC payload platform to Genentech, a member of the Roche Group, in a deal worth $45 million upfront and up to $1 billion in milestones plus tiered royalties, with DualityBio leading early development before Genentech takes over from Phase Ia through commercialization. Separately, Teva Pharmaceuticals submits a $57.5 million stalking-horse bid, plus up to $67.5 million in contingent payments, for worldwide rights to BioXcel Therapeutics' Igalmi (dexmedetomidine sublingual film) through a bankruptcy court-supervised auction, positioning the drug as a potential first at-home treatment for acute agitation ahead of its November 14 FDA target action date.

Finally, Israel Ortiz argues that preventive and predictive maintenance, paired with connected monitoring systems, are becoming essential tools for avoiding costly batch failures in biopharmaceutical manufacturing. Ortiz contends that even small deviations in a facility's environmental conditions can compromise product stability, and with batch failures striking roughly every 40 weeks and costing manufacturers millions of dollars in lost product, investigations, and delays, proactive maintenance is emerging as a critical quality lever across the industry.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.